These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 28664410

  • 1. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
    Tanabe H, Ando K, Sato K, Ito T, Goto M, Sato T, Fujinaga A, Kawamoto T, Utsumi T, Yanagawa N, Ichiishi E, Otake T, Kohgo Y, Nomura Y, Ueno N, Sugano H, Kashima S, Moriichi K, Fujiya M, Okumura T.
    Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
    [Abstract] [Full Text] [Related]

  • 2. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M.
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
    Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M.
    Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
    [Abstract] [Full Text] [Related]

  • 7. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance.
    Ashida K, Honda Y, Sanada K, Takemura Y, Sakamoto S.
    Expert Opin Drug Saf; 2019 Dec; 18(12):1255-1261. PubMed ID: 31646920
    [Abstract] [Full Text] [Related]

  • 8. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N.
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matsuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M, Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K.
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T.
    Ann Clin Microbiol Antimicrob; 2018 Jun 28; 17(1):29. PubMed ID: 29950163
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.
    Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K.
    Gut; 2020 Jun 28; 69(6):1019-1026. PubMed ID: 31915235
    [Abstract] [Full Text] [Related]

  • 18. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
    Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N.
    Helicobacter; 2017 Jun 28; 22(3):. PubMed ID: 28098408
    [Abstract] [Full Text] [Related]

  • 19. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H.
    Helicobacter; 2018 Aug 28; 23(4):e12495. PubMed ID: 29873436
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.